Advances in molecular diagnosis of HBV infection and drug resistance

International Journal of Medical Sciences

Volumn 2, Issue 1, 2005, Pages 8-16

  Sablon, Erwin ^a   Shapiro, Fred ^a  

^a INNOGENETICS   (Belgium)

Author keywords

Drug resistance; HBV infection; Molecular diagnosis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; LAMIVUDINE; VIRUS DNA;

CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DNA HYBRIDIZATION; DRUG EFFICACY; DRUG MONITORING; DRUG RESISTANCE; DRUG SAFETY; EVOLUTION; GENOTYPE; HEPATITIS B; HUMAN; INFECTION RISK; MEASUREMENT; MUTATION; QUANTITATIVE ANALYSIS; REVIEW; SEROLOGY; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 21644460342     PISSN: 14491907     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.2.8     Document Type: Review

References (64)

1. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-1241.
2. Bowden S. Laboratory diagnosis of hepatitis B infection. In: Lai CL, Locarnini S, eds. Hepatitis B Virus. London, UK: International Medical Press. 2002:145-159.
3. Hoofnagle JH, Dusheiko GM, Seef LB, et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-748.
4. Davis GL. Update on the management of chronic hepatitis B. Rev Gastroenterol Disord 2002;2:106-115.
5. Schutten M, Niesters HGM. Clinical utility of viral quantification as a tool for disease monitoring. Exp Rev Mol Diagn 2001;1:153-162.
6. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63-71.
7. Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003;38 (suppl 1):S90-S103.
8. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. New Engl J Med 1995;333:1657-1661.
9. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997;25:241-244.
10. Cooksley WGE, Piratvisuth T, Lee S-D, Mahachai V, Chao T, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatitis 2003;10:298-305.
11. Lai C, Chien R, Leung N, Chang T, Guan R, Tai D, et al. A one-year trial of lamivudine for chronic hepatitis B. New Engl J Med 1998;339:61-68.
12. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. New Engl J Med 1999;341:256-1263.
13. Lai C-L, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696.
14. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B. N Engl J Med 2003;348:808-816.
15. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
16. Westland CE, Yang H, Delaney WE 4th, Gibbs CS, Miller MD, Wulfsohn M, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003;38:96-103.
17. Yang H, Westland CE, Delaney WE 4th, Heathcote EJ, Ho V, Fry J, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-473.
18. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297.
19. Delaney WE 4th, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antiviral Chem Chemother 2001;12:1-35.
20. Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin Liver Dis 2002;22:23-31.
21. Doo E, Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001;120:1000-1008.
22. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Nat Acad Sci USA 1996;93:4298-4402.
23. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-757.
24. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001;21:243-253.
25. Clarke B, Bloor S. Molecular genotyping of hepatitis B virus. J Clin Virol 2002;25:S41-S45.
26. Aberle SW, Kletzmayr J, Watschinger B, Schmeid B, Vetter N, Puchhammer-Stockl E. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 2001;39:1972-1974.
27. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38:702-707.
28. Jardi R, Buti M, Rodriguez-Frias F, Cotrina M, Costa X, Pascual C, et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Meth 1999;83:181-187.
29. Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, et al. Two sensitive PCR-based methods for detection of hepatitis B variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999;37:3338-3347.
30. Niesters HGM, De Man RA, Pas SD, Fries E, Osterhaus ADME. Identification of a new variant in the YMDD motif of the hepatitis B polymerase gene selected during lamivudine therapy. J Med Microbiol 2002;51:695-699.
31. Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
32. Cane PA, Cook P, Ratcliffe D, Mutimer D, Pillay D. Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother 1999;43:1600-1608.
33. Whalley SA, Brown D, Teo CG, Dusheiko GM, Saunders NA. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler. J Clin Microbiol 2001;39:1456-1459.
34. Punia P, Cane P, Teo C-G, Saunders N. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol 2004;40:986-992.
35. Lok ASF, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002;40:3729-3734.
36. Southern E, Mir K, Shchepinov M. Molecular interactions on microarrays. Nat Genet 1999;21 (suppl):5-9.
37. Hall JG, Eis PS, Law SM, Reynaldo LP, Prudent JR, Marshall DJ, et al. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc Natl Acad Sci USA 2000;97:8272-8277.
38. Bai YJ, Zhao JR, Lv GT, Zhang WH, Wang Y, Yan XJ. Rapid and high throughput detection of HBV YMDD mutants with florescence polarization. World J Gastroenterol 2003;9:2344-2347.
39. Murray KK. DNA sequencing by mass spectrometry. J Mass Spectrom 1996;31:1203-1215.
40. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004;40:837-844.
41. Wilson JW, Bean P, Robins T, Graziano F, Persing DH. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-RT line probe assay. J Clin Microbiol 2000;38:3022-3028.
42. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-1088.
43. Kirishima T, Okanoue T , Daimon Y, Itoh Y, Nakamura H, Morita A, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002;37:259-265.
44. th International Symposium on Viral Hepatitis & Liver Disease (Abstract WE3-09); April 2003; Sydney Australia.
45. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-226.
46. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999;179:775-782.
47. Grandjacques C, Pradat P, Stuyver L, Chavallier M, Chavallier P, Pichoud C, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000;33:430-439.
48. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai Mmiyakawa Y, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988;69:2575-2583.
49. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995;38:24-34.
50. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67-74.
51. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059-2073.
52. Yuen MF, Sablon E, Tanaka Y, Kato T, Mizokami M, Doutreloigne J, et al. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. J Hepatol 2004;41:119-125.
53. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004;72:363-369.
54. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26.
55. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122:1756-1762.
56. Chan HL, Wong ML, Hui AY Hung LC, Chan FK, Sung JJ. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J Clin Microbiol 2003;41:1277-1279.
57. Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003;46:400-407.
58. Duong TN, Horiike N, Michitaka K, Yan C, Mizokami M, Tanaka Y, et al. Comparison of genotypes C and D of the hepatitis B virus in Japan: a clinical and molecular biological study. J Med Virol 2004;72:551-557.
59. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol. 2002;17:165-70.
60. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2003;123:1848-1856.
61. Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003;8:531-534.
62. Seo Y, Yoon S, Hamano K, Nakaji M, Yano Y, Katayama M, et al. Early response to interferon alpha treatment and long-term clinical outcome in Japanese patients with chronic HBV genotype C infection. Int J Mol Med 2004;13:75-79.
63. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-1430.
64. Chien RN Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained response to lamivudine therapy. Hepatology 2003;38:1267-1273.